Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients
- PMID: 33745714
- DOI: 10.1016/j.jtcvs.2021.02.014
Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients
Abstract
Background: Fontan physiology results in multiorgan dysfunction, most notably affecting the liver and kidney. We evaluated the utility of Model for End-Stage Liver Disease Excluding INR (MELD-XI) score, a score evaluating the function of both liver and kidney to identify Fontan patients at increased risk for morbidity and mortality post-heart transplant.
Methods: The Pediatric Heart Transplant Society database was queried to identify Fontan patients listed for heart transplant between January 2005 and December 2018. MELD-XI scores were calculated at listing and heart transplant. A multivariable analysis was conducted to identify risk factors for post-heart transplant mortality. Demographic, clinical characteristics, and survival differences were evaluated and compared between the high and low MELD-XI score cohorts. The impact of changing MELD-XI scores during the waitlist period on post-heart transplant outcomes was also evaluated.
Results: Of 565 Fontan patients who underwent transplantation, 524 (93%) had calculable MELD-XI scores at the time of heart transplant: 421 calculable at listing and 392 calculable at listing and at heart transplant. On multivariable analysis, only MELD-XI score (squared) (hazard ratio, 1.007), history of protein-losing enteropathy (hazard ratio, 2.1), and ventricular assist device use at transplant (hazard ratio, 3.4) were risk factors for early phase post-heart transplant mortality. Patients with high MELD-XI scores at heart transplant had inferior survival post-heart transplant (P = .02); those in the high MELD-XI score cohort at wait listing and heart transplant tend to have the worst post-heart transplant survival; however, this was not significant (P = .42).
Conclusions: The MELD-XI, an easily calculated score, serves as a valuable aid in identifying pediatric Fontan patients at increased risk for post-heart transplant mortality.
Keywords: Fontan transplant outcomes; Fontan-associated liver disease; MELD-XI; congenital heart disease; heart transplant; post-transplant survival; ventricular assist device.
Copyright © 2021 The American Association for Thoracic Surgery. All rights reserved.
Comment in
-
Commentary: The Fontan cardiac transplant-time to embrace change.J Thorac Cardiovasc Surg. 2022 Apr;163(4):1474-1475. doi: 10.1016/j.jtcvs.2021.02.053. Epub 2021 Feb 23. J Thorac Cardiovasc Surg. 2022. PMID: 33745717 No abstract available.
-
Commentary: The MELD-XI score in Fontan patients: It's about time.J Thorac Cardiovasc Surg. 2022 Apr;163(4):1475-1476. doi: 10.1016/j.jtcvs.2021.03.036. Epub 2021 Mar 16. J Thorac Cardiovasc Surg. 2022. PMID: 33838911 No abstract available.
-
Commentary: The Vulcan mind MELD-XI.J Thorac Cardiovasc Surg. 2022 Apr;163(4):1477-1478. doi: 10.1016/j.jtcvs.2021.03.052. Epub 2021 Mar 18. J Thorac Cardiovasc Surg. 2022. PMID: 33875260 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources